Mesenchymal Stem Cells Therapy in Patients With Recent Intracerebral Hemorrhage

NCT03371329 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2020-12-21

No results posted yet for this study

Summary

The overall goal of this study is to develop mesenchymal stem cell therapy for treatment of acute spontaneous hemorrhagic stroke.

Conditions

  • Hemorrhagic Stroke
  • Intracerebral Hemorrhage

Interventions

BIOLOGICAL

MSC

bone marrow derived cultured MSC (mesenchymal stem cell)

Sponsors & Collaborators

Principal Investigators

  • Abba C Zubair · Mayo Clinic

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-12-12
Primary Completion
2020-10-09
Completion
2020-10-09
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03371329 on ClinicalTrials.gov